amitriptyline has been researched along with Fecal Incontinence in 4 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Fecal Incontinence: Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amitriptyline, a tricyclic antidepressant agent with anticholinergic and serotoninergic properties has been used empirically in the treatment of idiopathic fecal incontinence with good results." | 9.09 | Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. ( Bartolo, DC; Eitan, BZ; Pryde, A; Santoro, GA, 2000) |
| "Amitriptyline, a tricyclic antidepressant agent with anticholinergic and serotoninergic properties has been used empirically in the treatment of idiopathic fecal incontinence with good results." | 5.09 | Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. ( Bartolo, DC; Eitan, BZ; Pryde, A; Santoro, GA, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casanova, MJ | 1 |
| Santander, C | 1 |
| Gisbert, JP | 1 |
| Beeckman, D | 1 |
| Van Damme, N | 1 |
| Schoonhoven, L | 1 |
| Van Lancker, A | 1 |
| Kottner, J | 1 |
| Beele, H | 1 |
| Gray, M | 1 |
| Woodward, S | 1 |
| Fader, M | 1 |
| Van den Bussche, K | 1 |
| Van Hecke, A | 1 |
| De Meyer, D | 1 |
| Verhaeghe, S | 1 |
| Santoro, GA | 1 |
| Eitan, BZ | 1 |
| Pryde, A | 1 |
| Bartolo, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Specific Factors Associated With the Development of Incontinence- Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence: Matched Case Control Study[NCT02996357] | 206 participants (Actual) | Observational | 2016-10-04 | Completed | |||
| A Turn and Positioning System and Standardized Incontinence Care Combined With Tailored Repositioning Versus a Standard Repositioning Protocol for Pressure Ulcer Prevention: A Multicenter Prospective Randomized Controlled Clinical Trial and Health Economi[NCT02690753] | 227 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Evaluate the Efficacy of Two Advanced Skin Treatment Regimens in Treating Incontinence-associated Dermatitis: Cluster Randomization Study[NCT04625426] | 86 participants (Actual) | Interventional | 2019-04-29 | Terminated (stopped due to Early termination due to COVID-19 pandemic led to inability to reach planned sample size) | |||
| Adjuvant Effect of Photobiomodulation in the Treatment of Incontinence-associated Dermatitis in Adults - a Randomized Controlled Clinical Trial[NCT05471180] | 0 participants (Actual) | Interventional | 2022-08-20 | Withdrawn (stopped due to The post graduated student change her project.) | |||
| Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis[NCT03685929] | 30 participants (Actual) | Observational | 2018-10-01 | Completed | |||
| Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence (Darifenacin for Treatment of Women With Dual Incontinence)[NCT03543566] | 32 participants (Actual) | Observational | 2018-05-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Examination of the development of skin loss using the Ghent Global IAD Categorisation tool (GLOBIAD).~Binary scoring, 1 and 2. Higher value (2) indicates worse outcome (Development of skin loss)" (NCT04625426)
Timeframe: Up to three days from initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| 3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant | 0 |
| Conveen EasiCleanse and Conveen Critic Barrier | 5 |
| Soap and Water / Incontinence Wipes and Conveen Critic Barrier | 3 |
Percentage of participants who experienced IAD healing (NCT04625426)
Timeframe: Up to seven days from initiation of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| 3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant | 35 |
| Conveen EasiCleanse and Conveen Critic Barrier | 32 |
| Soap and Water / Incontinence Wipes and Conveen Critic Barrier | 21 |
1 review available for amitriptyline and Fecal Incontinence
| Article | Year |
|---|---|
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
Interventions for preventing and treating incontinence-associated dermatitis in adults.
Topics: Administration, Topical; Adult; Amitriptyline; Dermatitis; Dermatologic Agents; Fecal Incontinence; | 2016 |
1 trial available for amitriptyline and Fecal Incontinence
| Article | Year |
|---|---|
Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricycli | 2000 |
2 other studies available for amitriptyline and Fecal Incontinence
| Article | Year |
|---|---|
Rectal hypersensitivity in patients with quiescent ulcerative colitis.
Topics: Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Colitis, Ulcerative; Fecal Incontinence; Humans; | 2015 |
Wetting and soiling.
Topics: Amitriptyline; Child; Enuresis; Fecal Incontinence; Humans; Imipramine | 1972 |